Today's Breaking News
Latest R&D and Business News
- ChemoCentryx Announces Phase I Data With CCX507, Company's New Generation Orally Administered CCR9 Inhibitor
- Biogen Idec Submits Application to FDA for Approval of PLEGRIDY (Peginterferon Beta-1a) in Multiple Sclerosis
- Ferumoxytol Treatment Produced Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Gastrointestinal Disease Who Had Failed or Could Not Tolerate Oral Iron Therapy
- Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
- Baxter Receives Marketing Authorization for HyQvia in European Union
- Phase III results: tiotropium Respimat effective in symptomatic asthma patients despite at least ICS/LABA independent of their age, allergic status, smoking status and bronchodilator response
- Sunovion Pharmaceuticals Inc. Presents Data Showing 12 Months of Latuda (lurasidone HCl) Treatment Resulted in Higher Remission Rates in Adult Patients with Schizophrenia Compared to Seroquel XR (quetiapine XR)
- Jennerex Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
- AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
- AB Science : Launch of a Phase 3 Clinical Trial in Alzheimer's Disease
- Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics For Monogenic Diseases
- Rockwell Medical Presents PRIME Study Results at the 50th ERA-EDTA Meeting in Istanbul, Turkey